Initiate limited dose-ranging studies of ULTOMIRIS in HSCT-TMA
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Jan 2020
- Due
- 30 Jun 2020
- Checked
- 21 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Alexion plans to initiate limited dose-ranging studies of ULTOMIRIS in adults and children with HSCT-TMA in the first half of 2020”
What we found
Evidence strength A What the grades mean
The company failed to initiate the studies in the first half of 2020, explicitly pushing the timeline to the second half of 2020 in a filing dated July 30, 2020.
-
A Alexion Pharmaceuticals 8-K filed 2020-07-30
“Alexion plans to initiate limited dose-ranging studies of ULTOMIRIS in HSCT-TMA in the second half of 2020” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +184 days
- 2 versions
-
Version 1 · original · stated 30 Jan 2020
Deadline 30 Jun 2020 (“in the first half of 2020”) · wording expected
-
Version 2 · stated 6 May 2020
Deadline 31 Dec 2020 (“second half of 2020”) · wording expected
“Alexion plans to initiate limited dose-ranging studies in the second half of 2020”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Dose-ranging studies of ULTOMIRIS in HSCT-TMA
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019366 · Corrections policy